What is NovoSeven®?
NovoSeven® is activated recombinant factor VII (rFVIIa). Factor VII (FVII) is a naturally occurring blood protein that is present in the human plasma. FVII becomes activated when there is a need to stop a spontaneous bleed or a bleed occurring after some kind of injury. By applying recombinant DNA techniques, it has been possible to make a copy of this naturally occurring protein. Novo Nordisk has developed NovoSeven® for the treatment of spontaneous bleeds and for coverage during surgery in patients with haemophilia and inhibitors (antibodies) against factor VIII (FVIII) and factor IX (FIX) (haemophilia A and B with inhibitors).